Complete Remission After Single Agent Blinatumomab in a Patient with Pre-B Acute Lymphoid Leukemia Relapsed and Refractory to Three Prior Regimens: HyperCVAD, High Dose Cytarabine Mitoxantrone and CLAG

Authors

Katherine Linder, New York Medical CollegeFollow
Deepthi Gandhiraj, New York Medical CollegeFollow
Madhura Hanmantgad, New York Medical CollegeFollow
Karen Seiter, New York Medical CollegeFollow
Delong Liu, New York Medical CollegeFollow

First Page

20

Last Page

20

Document Type

Article

Publication Date

7-26-2016

Department

Medicine

Abstract

BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.

CASE PRESENTATION: We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.

CONCLUSION: This highly refractory pre-B Ph(-) ALL was induced to complete remission after one course of single agent blinatumomab.

Recommended Citation

Linder, K., Gandhiraj, D., Hanmantgad, M., Seiter, K, & Liu, D.(2016). Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: HyperCVAD, high dose cytarabine mitoxantrone and CLAG. Experimental Hematology & Oncology, 5, 20. doi:10.1186/s40164-016-0051-4

Publisher's Statement

Originally published in Experimental Hematology & Oncology. Licensed under CC-BY 4.0. https://doi.org/10.1186/s40164-016-0051-4